Video+

Xenofon Baraliakos takes us through SURPASS, a phase 3b head-to-head trial that demonstrated equivalence of secukinumab versus adalimumab biosimilar in patients with radiographic axial spondyloarthritis.

Following publication of the ORAL Surveillance trial, Richard Conway and Kevin Winthrop discuss the impact of the findings on JAK inhibitor prescribing, how regulatory recommendations compare in Europe and the USA, and whether the risks seen with tofacitinib represent a class effect.

Following the results of the ORAL Surveillance trial, which demonstrated increased rates of adverse events in people taking JAK inhibitors, Victoria Ruffing provides guidance on how to talk to patients about the risks associated with these medications.

Fabian Proft discusses the potential impact of bimekizumab on the treatment of radiographic and nonradiographic axial spondyloarthritis in light of findings from the BE MOBILE 1 and 2 trials.

Philippe Carron comments on the findings from the BE COMPLETE and BE OPTIMAL studies, and discusses how bimekizumab may impact the psoriatic arthritis treatment landscape if approved by the regulatory authorities.

Désirée van der Heijde outlines the findings of two phase 3 trials demonstrating that bimekizumab may be beneficial for patients with nonradiographic axial spondyloarthritis or ankylosing spondylitis.

Joseph Merola talks about the BE COMPLETE and BE OPTIMAL trials, which showed that the dual IL-17A/IL-17F inhibitor bimekizumab is a promising treatment option for psoriatic arthritis patients with and without prior exposure to TNF inhibitors.

Roy Fleischmann discusses the implications of the CREDO2 and 3 trial findings looking at olokizumab efficacy versus adalimumab as an add-on to methotrexate and in TNF inhibitor non-responders.

Laura Coates comments on the results of the KEEPsAKE 1 and 2 studies, and explores where risankizumab may fit in the treatment landscape for psoriatic arthritis.

Jürgen Rech outlines the findings from the ARIAA trial, which demonstrated benefits of abatacept in people at risk for rheumatoid arthritis, and discusses the potential role of treating subclinical inflammation to delay or prevent the onset of clinical disease.

Pedro Machado presents COVID-19 vaccine safety data supporting their use for patients with rheumatic and musculoskeletal diseases.

Andrew Östör talks about the results of KEEPsAKE 2, a phase 3 trial of risankizumab versus placebo in patients with psoriatic arthritis, and explores how the IL-23 inhibitor may impact clinical practice if approved by the regulatory authorities.

Robert Spiera discusses the phase 3 RESOLVE-1 findings for lenabasum in patients with diffuse cutaneous systemic sclerosis, highlighting the possible effects of background immunosuppressive therapy on outcome.

Laura Coates outlines the findings from a phase 3b trial of guselkumab versus placebo in patients with psoriatic arthritis and an inadequate response to TNF inhibitors.

Jeffrey Sparks and Zachary Wallace talk about the potential for COVID-19 being more severe in rheumatoid arthritis patients treated with rituximab or JAK inhibitors rather than TNF inhibitors.

We asked Aruni Jayatilleke, author on the American College of Rheumatology’s telemedicine position statement, to share her top tips on how to provide the best care via telemedicine (1:09).

We asked Chris Phillips, author on the American College of Rheumatology’s telemedicine position statement, to share his top tips on how to provide the best care via telemedicine (1:09).

Denis Poddubnyy reports on the spinal pain improvements seen with secukinumab in patients with axial spondyloarthritis, including the benefit of up-titration for suboptimal responders.

Richard Furie discusses the potential benefits of BIIB059, an antibody that blocks blood dendritic cell antigen 2, in the treatment of systemic lupus erythematosus and the science behind its phase 2 success.

Marina Magrey comments on a phase 3 trial of the JAK inhibitor tofacitinib versus placebo in patients with ankylosing spondylitis.